## Mankind Pharma Limited (MANKIND) Stock Analysis - December 20, 2024

This report analyzes the provided data for Mankind Pharma Limited (MANKIND) to determine whether it's a buy, sell, or hold.  The analysis is based solely on the provided data and does not consider external market factors or sentiment.

**1. Data Preprocessing:**

The provided data has been parsed and organized into the following sections:

**1.1 Company Profile:**

| Field             | Value                     |
|----------------------|--------------------------|
| Symbol              | MANKIND                   |
| Company Name        | Mankind Pharma Limited     |
| Industry            | Pharmaceuticals           |
| Listing Date        | May 9, 2023               |
| ISIN                | INE634S01028              |


**1.2 Market Data:**

| Field                | Value      |
|-----------------------|-------------|
| Last Price            | 2,800.00    |
| Change                | -91.05     |
| % Change              | -3.15%      |
| Previous Close        | 2,891.05    |
| Open                  | 2,907.80    |
| Close                 | 2,805.20    |
| VWAP                  | 2,834.73    |
| Week High             | 2,922.90    |
| Week Low              | 1,851.05    |
| Sector PE             | 54.51      |
| Symbol PE             | 54.51      |
| Delivery to Traded % | 41.45%     |


**1.3 Pre-Open Market Data:**

The pre-open market showed a higher opening price (2907.8) compared to the previous close, indicating initial buying interest. However, the final price closed significantly lower.

**1.4 Corporate Actions:**

No dividends or other corporate actions were reported in the provided data.

**1.5 Recent Announcements:**

Several announcements were made, including those related to capital alteration, fund raising, securities allotment, and Qualified Institutional Placements (QIPs).  These suggest significant corporate activity.  Specific details require further investigation beyond the provided subject lines.

| Date       | Subject                                      |
|------------|----------------------------------------------|
| Dec 20, 2024 | Alteration Of Capital and Fund Raising-XBRL |
| Dec 20, 2024 | Allotment of Securities                     |
| Dec 19, 2024 | Qualified Institutional Placement             |
| Dec 16, 2024 | Qualified Institutional Placement             |
| Dec 16, 2024 | General Updates                             |
| Dec 12, 2024 | General Updates                             |
| Dec 4, 2024  | Analysts/Institutional Investor Meet/Con. Call Updates |
| Dec 3, 2024  | Sale or disposal-XBRL                       |


**1.6 Financial Results (Last Five Quarters):**

| Quarter      | Income       | Expenditure  | Profit After Tax | EPS     |
|--------------|--------------|---------------|--------------------|---------|
| Q3 FY25      | 263,550      | 186,505       | 63,443            | 15.04   |
| Q2 FY25      | 249,809      | 192,072       | 51,349            | 12.09   |
| Q1 FY25      | 223,654      | 169,168       | 45,417            | 11.34   |
| Q4 FY24      | 242,580      | 184,945       | 48,707            | 12.16   |
| Q3 FY24      | 251,146      | 189,950       | 47,288            | 11.80   |


**1.7 Shareholding Patterns:**

Promoter holding has decreased from 76.50% in Sep 2023 to 74.87% in Sep 2024.  This is a relatively small decrease, but it's important to note.  The 'ndsid' column in the data appears to be an internal identifier and doesn't directly impact the analysis.

**1.8 Board Meetings:**

Several board meetings were held, primarily to discuss financial results and fund-raising activities.

**1.9 Key Management Personnel:**

(List of directors and their designations are available in the provided data but omitted here for brevity.  This information is readily accessible in the original data.)

**1.10 Contact Information:**

(Registrar and company contact details are available in the provided data but omitted here for brevity. This information is readily accessible in the original data.)


**2. Key Indicators:**

**2.1 Current Price Analysis:**

* The current price (2,800.00) is significantly lower than the day's open (2,907.80) and the week's high (2,922.90), indicating a bearish trend.
* The significant drop from the previous close (-91.05) and the negative percentage change (-3.15%) further reinforce the bearish sentiment.

**2.2 Financial Performance:**

* Revenue shows some fluctuation but generally positive growth over the last five quarters.
* Profit after tax and EPS also show some fluctuation but generally positive growth.  However, the most recent quarter shows a slight decrease in profit and EPS compared to the previous quarter.

**2.3 Shareholding Analysis:**

* A slight decrease in promoter holding is observed over the past year.  This could indicate potential future dilution.

**2.4 Corporate Action Summary:**

* No corporate actions (like dividends) were reported in the provided data.

**2.5 Volatility and Risk:**

* The data provides daily and annual volatility metrics (1.85% and 35.34% respectively).  This suggests moderate to high volatility, indicating higher risk.

**2.6 Key Directors and Contact Info:**

(This information is available in the original data but omitted here for brevity.)


**3. Final Verdict:**

**Hold.**

**Reasoning:**

While the company shows generally positive financial performance with increasing revenue and profit over the past year, the recent price drop is concerning. The decrease in promoter holdings, coupled with the high volatility and lack of dividend announcements, adds to the uncertainty.  The numerous announcements regarding fund-raising and QIPs suggest significant corporate activity, which could be positive or negative depending on the specifics of these actions.  More information is needed to assess the impact of these announcements.  Until more clarity is available, a "Hold" recommendation is prudent.

**Conclusion:**

Based on the available data, Mankind Pharma Limited presents a mixed picture.  Positive financial growth is offset by recent price volatility and a slight decrease in promoter holdings.  The numerous corporate announcements require further investigation before a definitive buy or sell recommendation can be made.  Therefore, a "Hold" verdict is the most appropriate course of action at this time.
